Perceptive Advisors
VC Fund
New York, United States
Perceptive Advisors is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while investing. The firm typically invests in the biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York,New York.
- Total investments:
- 371
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $515M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Perceptive Advisors invests in
Stages Perceptive Advisors invests in
Countries Perceptive Advisors invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Investment Focus
Industry
- Biotechnology 202 (54%)
- Health Care 155 (42%)
- Medical 94 (25%)
- Therapeutics 80 (22%)
- Pharmaceutical 80 (22%)
Stage
- Post-IPO Equity 86 (23%)
- Series B 63 (17%)
- Series C 46 (12%)
- Series A 31 (8%)
- Post-IPO Debt 23 (6%)
Country
- United States 205 (55%)
- United Kingdom 10 (3%)
- Canada 7 (2%)
- France 6 (2%)
- China 4 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ellen Hukkelhoven
Head of Investment Research
|
Head of Investment Research | Total investments: 9 | Find email | |
Fred Callori
Managing Director of Venture
|
Managing Director of Venture | Total investments: 8 | Find email | |
Joseph Edelman
CEO & Founder
|
CEO & Founder | Total investments: 12 | Find email | |
Orly Mishan
Managing Director, Perceptive Discovery
|
Managing Director, Perceptive Discovery | Total investments: 0 | Find email | |
Adam Stone
Chief Investment Officer
|
Chief Investment Officer | Total investments: 8 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Lisata Therapeutics is a clinical-stage pharmaceutical company developing therapies based on clear differentiation and rigorous data applied in areas of high unmet medical need. They focus on the discovery, development, and commercialization of therapies for the treatment of solid tumors and other major diseases. | $225M / Post-IPO Equity / Sep 17, 2026 | ||
| Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development. Its platform creates candidate-ready compounds with speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. | $65.5M / Series B / Sep 03, 2026 | ||
| DocGo is a telehealth company offering mobile medical services, on-site event medical services, and transportation services. | $12.5M / Post-IPO Debt / Aug 17, 2026 | ||
| Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. | $7M / Post-IPO Equity / Aug 14, 2026 | ||
| Vaderis Therapeutics is a biotechnology company in the clinical stages that specializes in the treatment of uncommon and orphan diseases. | $152M / Series B / Aug 11, 2026 | ||
| Ensysce Biosciences develops oral drug delivery technologies targeting opioid misuse and overdose. Its Trypsin-Activated Abuse Protection (TAAP™) platform activates medications only upon ingestion, minimizing abuse through non-oral routes. The Multi-Pill Abuse Resistance (MPAR®) system adds a safeguard against overdose by inhibiting drug activationwhen excessive doses are consumed. These platforms are applied to treatments for severe pain and opioid use disorder, including PF614 and PF9001. Ensysce's approach has received recognition from the FDA, with TAAP™ designated as a Fast Track development and MPAR® as a Breakthrough Therapy. The company is also exploring the use of nafamostat, a component of its overdose protection products, for treating infections and pulmonary diseases. Its pipeline includes clinical and preclinical programs focused on enhancing the safety of prescription medications. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. | $21.5M / Post-IPO Equity / Aug 06, 2026 | ||
| Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience andnetworks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience. | $275M / Post-IPO Equity / Jul 27, 2026 | ||
| Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $240M / Post-IPO Equity / Jul 20, 2026 | ||
| CereVasc is a medical device company that develops treatments for neurological diseases, with a primary focus on communicating hydrocephalus. The company is advancing the eShunt® System, an investigational device designed to manage cerebrospinal fluid through a minimally invasive endovascular approach rather than traditional open neurosurgery. Itstechnology includes an implantable cerebrospinal fluid shunt and associated delivery components intended to treat hydrocephalus while reducing the need for invasive surgical procedures. CereVasc conducts clinical studies to evaluate the safety and effectiveness of the eShunt System in patients with conditions such as normal pressure hydrocephalus and other forms of communicating hydrocephalus. The company’s work centers on developing device-based therapies that improve access to treatment for patients with neurological disorders. | $85M / Series C / Jun 04, 2026 | ||
| Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M / Post-IPO Equity / May 18, 2026 | ||
| See all 371 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Perceptive Advisors invest in?
Perceptive Advisors invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Series B stage. Most of the 371 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Perceptive Advisors?
Public channels for Perceptive Advisors include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Perceptive Advisors?
The team at Perceptive Advisors includes Ellen Hukkelhoven (Head of Investment Research), Fred Callori (Managing Director of Venture) and Joseph Edelman (CEO & Founder), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
